Roche (OTCQX: RHHBY) to Acquire PathAI to Advance AI Diagnostics

May 7, 2026

Expert Analysis Roche (OTCQX: RHHBY) is making a strategic move to deepen its foothold in the digital pathology and AI-driven diagnostics space by acquiring PathAI. This acquisition underscores Roche’s commitment to leveraging artificial intelligence to revolutionize pathology workflows and enhance diagnostic precision. By integrating PathAI’s advanced AI-powered technologies with its current capabilities, Roche aims to transform how diagnostic data supports patient care and drug development. The merger also builds upon…

Read More >>